IC
WHWK

Ikarian Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Ikarian Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-412,343
Closed -$1.27M – 166
2022
Q2 		$1.27M Buy
412,343
+203,975
+98% +$3.03M 0.23% 71
2022
Q1 		$3.54M Buy
208,368
+11,960
+6% +$229K 0.47% 51
2021
Q4 		$4.74M Buy
196,408
+185,000
+1,622% +$4.65M 0.71% 38
2021
Q3 		$335K Sell
11,408
-100,332
-90% -$3.06M 0.02% 195
2021
Q2 		$2.83M Sell
111,740
-65,000
-37% -$1.48M 0.23% 103
2021
Q1 		$3.42M Buy
176,740
+145,021
+457% +$3.34M 0.12% 158
2020
Q4 		$468K Sell
31,719
-231,112
-88% -$4.94M 0.02% 193
2020
Q3 		$5.91M Buy
+262,831
New +$5.53M 0.43% 61

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital's WHWK Position: Q3 2022 in Review

Ikarian Capital sold out of Whitehawk Therapeutics (WHWK) in Q3 2022, closing a stake of 412,343 shares — an estimated $1.27M sold.

Ikarian Capital first reported a position in WHWK in Q3 2020 and held it in 8 quarters. The position peaked at $5.91M in Q3 2020. 68 funds tracked by Wall St. Rank hold WHWK as of Q3 2022.

  • Ikarian Capital reported no remaining Whitehawk Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 412,343 Whitehawk Therapeutics shares in Q3 2022, an estimated $1.27M.
  • Ikarian Capital first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 8 quarters.
  • Ikarian Capital's Whitehawk Therapeutics position peaked at $5.91M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.